98%
921
2 minutes
20
Bronchial artery embolization (BAE) is a safe and effective treatment for hemoptysis, which is caused by diseases such as lung cancer, bronchiectasis, and tuberculosis. In cases of massive hemoptysis, the offending vessel originates from the bronchial artery in more than 90% of cases, and in a few cases, it can originate from nonbronchial arteries. Superselective embolization of complex or rarely affected vessels remains challenging. The SwiftNINJA steerable microcatheter (SSM) (Merit Medical) optimizes the navigation of complex vessels through preset tip angles. We present a case of massive hemoptysis caused by lung cancer, in which the offending artery originated from the right thyrocervical trunk, which was at an acute angle (<30°) relative to the right subclavian artery. After conventional microcatheter techniques failed in superselection, the SSM was selected based on the anatomical characteristics of the bleeding vessel during the procedure. By setting the preset angle of its tip, we could quickly and accurately pass it through the right subclavian artery and hook its branch arteries, thereby easily superselecting and embolizing the bleeding vessel. Through the use of SSM, superselection and embolization of difficult angles can be successfully achieved. SSM improves the efficiency of superselective embolization in BAE surgery.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12268476 | PMC |
http://dx.doi.org/10.21037/jtd-2025-815 | DOI Listing |
Zhonghua Jie He He Hu Xi Za Zhi
September 2025
Department of Respiratory and Critical Care Medicine, the First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China.
Tracheobronchial Dieulafoy's disease (TBDD) is a rare bronchial artery vascular malformation, characterized clinically by sudden, recurrent, and life-threatening massive hemoptysis. This article reports the case of a 9-year-old female patient who presented with massive hemoptysis lasting two weeks. Following ineffective treatment at a local hospital, she was transferred to our institution.
View Article and Find Full Text PDFCureus
July 2025
Otolaryngology - Head and Neck Surgery, King Fahad Armed Forces Hospital, Jeddah, SAU.
Fungal pseudoaneurysms of the internal carotid artery (ICA) are rare, life-threatening complications of invasive fungal sinusitis, particularly in immunocompromised patients. These pseudoaneurysms typically occur in the cavernous segment due to its proximity to the sphenoid sinus and often present with massive epistaxis or neurological deficits. The supraclinoid ICA segment is a rare location for these aneurysms and carries risks of both intracranial and sinonasal hemorrhage.
View Article and Find Full Text PDFEur Radiol
August 2025
Department of Radiology, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, China.
Objective: Massive haemoptysis due to central pulmonary artery (CPA) rupture in patients with advanced lung cancer is a fatal complication with limited early diagnostic tools. This study aimed to identify risk factors associated with pulmonary artery rupture and to propose a grading model to facilitate early diagnosis and timely endovascular intervention.
Materials And Methods: This retrospective study included patients with advanced lung cancer who experienced in-hospital sudden haemoptysis-related death and received endovascular treatment for CPA abnormalities.
Pulmonary artery pseudoaneurysms (PAAs) are exceedingly uncommon. It is a life-threatening diagnosis, and often associated with poor long-term prognosis. We report a case of PAA in a 74-year-old man presenting with severe respiratory failure and haemoptysis with a history of advanced lung cancer.
View Article and Find Full Text PDFFront Surg
August 2025
Department of Endoscopy, Henan Provincial Chest Hospital, Zhengzhou, Henan, China.
Background: To explore the short-term prognosis, mid- and long-term clinical follow-up of bronchoscopic intervention therapy (BIT) combined with bronchial artery embolization (BAE) in the treatment of massive hemoptysis.
Methods: Patients with massive hemoptysis who received BAE (BAE group) or BAE combined with BIT (BAE & BIT group) based on standard clinical treatment were included retrospectively, during June 2022 and March 2023. The short-term prognosis assessed by the therapeutic response, hemoptysis recurrence rates at 1-month post-surgery, and postoperative complications were compared.